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Background: Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach
from the primary cancer and survive in distant organs. The aim of the present study was to develop a CTC gene
signature and to assess its prognostic relevance after surgery for pancreatic ductal adenocarcinoma (PDAC).
Methods: Negative depletion fluorescence activated cell sorting (FACS) was developed and validated with spiking
experiments using cancer cell lines in whole human blood samples. This FACS-based method was used to enrich
for CTC from the blood of 10 patients who underwent surgery for PDAC. Total RNA was isolated from 4 subgroup
samples, i.e. CTC, haematological cells (G), original tumour (T), and non-tumoural pancreatic control tissue (P). After
RNA quality control, samples of 6 patients were eligible for further analysis. Whole genome microarray analysis was
performed after double linear amplification of RNA. ‘Ingenuity Pathway Analysis’ software and AmiGO were used for
functional data analyses. A CTC gene signature was developed and validated with the nCounter system on
expression data of 78 primary PDAC using Cox regression analysis for disease-free (DFS) and overall survival (OS).
Results: Using stringent statistical analysis, we retained 8,152 genes to compare expression profiles of CTC vs. other
subgroups, and found 1,059 genes to be differentially expressed. The pathway with the highest expression ratio in
CTC was p38 mitogen-activated protein kinase (p38 MAPK) signaling, known to be involved in cancer cell
migration. In the p38 MAPK pathway, TGF-β1, cPLA2, and MAX were significantly upregulated. In addition, 9 other
genes associated with both p38 MAPK signaling and cell motility were overexpressed in CTC. High co-expression of
TGF-β1 and our cell motility panel (≥ 4 out of 9 genes for DFS and ≥ 6 out of 9 genes for OS) in primary PDAC
was identified as an independent predictor of DFS (p=0.041, HR (95% CI) = 1.885 (1.025 – 3.559)) and OS (p=0.047,
HR (95% CI) = 1.366 (1.004 – 1.861)).
Conclusions: Pancreatic CTC isolated from blood samples using FACS-based negative depletion, express a cell
motility gene signature. Expression of this newly defined cell motility gene signature in the primary tumour can
predict survival of patients undergoing surgical resection for pancreatic cancer.
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The vast majority of patients suffering from solid organ
malignancies ultimately die from metastases, irrespective
of the type of treatment modality [1]. Current cancer
treatments are mainly based on primary tumour
characterization instead of on characterization of metas-
tases or cancer cells in the blood circulation. Since dis-
tant organ metastases are the end-results of circulating
tumor cells (CTC), molecular characterization of CTC is
promising in the quest for effective therapeutic agents
and novel prognostic markers [2].
Unfortunately, specific isolation of CTC has proved dif-
ficult. Identification and isolation of CTC using prede-
fined marker expression has failed to identify certain
cancer cell phenotypes, and consequently also their ge-
notypes. Methods to isolate, identify and enable reliable
and reproducible molecular characterization of CTC
without a priori selection could provide new insights into
cancer research and improve management of the disease.
The aim of the present study was to develop a negative
depletion strategy to enrich whole blood for CTC with-
out excluding any particular subset of CTC, and to study
their gene-expression profiles in order to find novel




Fresh tumour (T) and surrounding non-tumoural control
(P) tissue samples were obtained from surgical specimens
from 10 patients (M/F: 5/5; median age (range): 61,0 (50 –
74) years) who had undergone surgical resection for pan-
creatic ductal adenocarcinoma (PDAC) (Table 1). To verify
that samples contained more than 70% tumour tissue,
hematoxylin and eosin stains were made from each













77 Female 63 PDAC 3 3 1 2b
87 Male 57 PDAC 1 3 1 2b
88 Female 48 PDAC 2 3 1 2b
90 Male 59 PDAC 1 3 0 2a
91* Female 51 PDAC 3 3 0 2a
104* Female 72 PDAC 3 3 1 2b
105* Male 68 PDAC 3 2 0 1b
117* Female 72 PDAC 3 3 0 2a
123* Male 74 PDAC 3 1 1 2b
138* Male 50 PDAC 2 2 1 2b
PDAC: pancreatic ductal adenocarcinoma. * indicates patients of whom all
samples reached RNA quality standards set for microarray analysis.tissue to confirm its non-cancerous histology. Tissue sam-
ples were immediately submerged in RNAlaterW (Qiagen)
and stored at −80°C. From the same 10 patients, 20ml of
EDTA-treated venous blood was drawn intra-operatively
via a central venous line, immediately after removal of
the resection specimen. Patient recruitment started
after approval of the study by the ethical committee of
the University Hospital Leuven (Ref. ML 3452) and
complete registration of the protocol at Clinicaltrials.gov
[NCT00495924]. The research reported was undertaken
in compliance with the Helsinki Declaration. Informed
consent was obtained from all patients included.
Fluorescence activated cell sorting (FACS)
Blood samples were incubated on ice in OncoquickW
tubes (Greiner Bio-One, GmbH, Kremsmünster, Austria)
for 10–15 minutes [3,4]. Enrichment of tumour cells was
obtained by density gradient centrifugation following the
manufacturer’s recommendations at a centrifugation ac-
celeration of 1400g. The interphase was collected and
washed twice with washing buffer. The cell pellet was
then resuspended in 400ml phosphate buffered saline
(PBS) and transferred to a polystyrene FACS-tube. Sub-
sequently, the cells were stained by incubating at 4°C
with 20μl of directly conjugated anti-CD45 and anti-
CD34 FITC-labelled antibodies (BD Biosciences) for 30
minutes. The sample was washed and resuspended in
1ml of PBS. Non-viable cells were stained by incubation
with 10μl of the 7-amino-actinomycin D (Calbiochem,
Merck Chemical Ltd, Nottingham, UK) for 15–30 minutes.
The analysis was done on a FACSDiva™ 6.0 upgraded
FACSVantage™ SE cell sorter (BD Biosciences). A negative
depletion procedure was used to enrich for CTC, combin-
ing gates containing CD45 negative and CD34 negative
cells in addition to 7-amino-actinomycin D viability stain-
ing to exclude all haematological and non-viable (G frac-
tion) cells (Figures 1 and 2). Photomultiplicator (PMT)
settings were chosen based on fluorophore-labelled beads.
For gene expression analysis all fractions were directly
sorted in RLT (Qiagen) on ice.
Spiking experiments
The Panc-1 pancreatic cancer cell line was purchased
from the American Type Culture Collection (ATCC;
CRL-1469, ABPromochem) [5]. Panc-1 cells were cul-
tured at 37°C in DMEM supplemented with 10% foetal
bovine serum, penicillin and streptomycin.
Two different concentrations of Panc-1 cells (5.0 × 104
and 5.0 × 106 cells) were spiked in duplo in 20ml of
EDTA-treated blood obtained from healthy volunteers,
and gently versed in an OncoquickW tube. The recovered
cell populations (CTC- and G-fractions) were FACS-
sorted in CytoRichW red and cytospins were made by
spinning the cells at 800 rpm for 10min. Slides were air-
Figure 1 Density plot showing how 7-AAD positive non-viable
cells were excluded from viable cells.
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1:30, Novacastra) was carried out. Cells were counter-
stained with haematoxylin. An experienced pathologist
(TR) semi-quantitatively scored the relative distribution
of cell populations.
RNA isolation
RNA was isolated from tissue sections using a protocol
combining Trizol/chloroform extraction, followed byFigure 2 Density plot presenting viable cells and exclusion of
CD45CD34-FITC positive and negative cells. CTC population is a
subpopulation of viable cells. CTC: circulating tumour cells.column chromatography with the RNeasy Mini kit
(Qiagen). Briefly, after homogenization of the tissue
with 500μl of TrizolW (Invitrogen), 100μl of chloroform
was added followed by mixing until a milky solution
was obtained.
This mixture was then centrifuged at 12.000 rpm in a
cooled benchtop centrifuge for 25 minutes. Subse-
quently, the supernatant was removed and added to an
equal amount of 70% ethanol. After this step the RNeasy
Mini kit was followed according to the manufacturer’s
recommendations.
RNA from the FACS sorted cell populations was
prepared using the RNeasy Micro kit (Qiagen), in-
cluding a DNase step according to the manufacturer’s
recommendations.
Array hybridization
RNA concentration and purity were determined spectro-
photometrically using the Nanodrop ND-1000 (Nano-
drop Technologies) for all samples. RNA integrity of the
T and P samples was assessed using a Bioanalyser 2100
(Agilent). Per sample, ideally an amount of 5–10 ng of
total RNA spiked with four bacterial RNA transcripts
(Affymetrix) was converted and amplified to double-
stranded cDNA in a 2-cycle cDNA reverse transcription
reaction. Subsequently, the sample was converted to
antisense cRNA and labelled with biotin through an
in vitro transcription reaction according to the manufac-
turer’s protocol (Affymetrix). Purified fragmented bioti-
nylated cRNA and hybridization controls (Affymetrix)
were mixed, hybridized on Affymetrix HG U133 Plus 2.0
arrays, and subsequently stained and washed in the Gene-
Chip fluidics station 450 (Affymetrix). To assess the raw
probe signal intensities, chips were scanned using the
GeneChip scanner 3000 (Affymetrix).
Microarray data analysis
R, a free software environment for statistical computing
and graphics, was used in combination with the affy and
limma libraries in Bioconductor for microarray data ana-
lysis [6-9]. To decide whether a signal was significantly
above background, the MAS 5.0 algorithm was applied
to calculate probe set detection calls. Robust Multichip
Average (RMA) was applied to probe sets that had a
present detection call in at least 4 out of 6 CCD samples.
Using limma, the average expression value for each ex-
perimental condition was estimated. Based on these esti-
mates, the contrasts CTC vs. T, CTC vs. P, CTC vs. G, T
vs. P, T vs. G, and P vs. G were estimated. A moderated
t-statistic (implemented in limma) was used to test
whether each contrast was significantly different from 0
Resulting p-values were corrected for multiple testing
with Benjamini-Hochberg (BH) to control for false dis-
covery rates [10]. Subsequently, a filter was applied
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OR downregulated using the BH corrected p-values (p <
0.05) in the comparisons CTC vs. T, AND in CTC vs. P,
AND CTC vs. G. The resulting filtered data were func-
tionally analyzed with the Ingenuity Pathway Analysis
(IPA) application (IngenuityW Systems, www.ingenuity.
com). Gene networks were generated within the Ingenuity
Pathway Analysis programme, and ordered by a score.
This score is a numerical value used to rank networks
according to their degree of relevance to the Network Eli-
gible molecules in the dataset. The network score is based
on hypergeometric distribution and is calculated with the
Ingenuity Pathway Analysis programme using the right-
tailed Fisher's Exact Test. The set of genes upregulated in
CTC vs. T, AND in CTC vs. P, AND CTC vs. G was fur-
ther explored for genes associated with cell motility using
AmiGO, the GO Consortium’s annotation and ontology
tool kit [11]. Gene expression data are publicly available
online via: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=zbotdukywssgujm&acc=GSE18670.
Validation of gene signature
Between 2006 and 2010, tissue samples were obtained
from patients who had undergone pancreatic resection
for PDAC. Samples were stored at −80°C in RNAlaterW
(Qiagen). To verify that the tumor samples contained
more than 70% tumor, hematoxylin and eosin stains
were made from each tumour sample and from sur-
rounding control pancreatic tissue to confirm its
non-cancerous histology. True cellularity was not deter-
mined. From the primary tumour of 143 patients and
from surrounding non-tumoural pancreatic (control) tis-
sue of 14 patients, total RNA was extracted using the
RNeasy Mini kit according the manufacturer’s instruc-
tions. Only samples with an RNA integrity number
(RIN) of ≥ 7.0 were used for further analysis, i.e. 78
PDAC-samples (M/F = 40/38, median age 64 y. (range
32–80 y.)) and 6 controls. A limited set of genes was
selected based on the results from the microarray gene
expression analysis in CTC. Using the nCounter system
(Nanostring Technologies, Seattle, WA) gene expression
levels were quantified at the VIB Nucleomics Core of the
VIB Microarray Facility.
Survival analysis
Median overall survival (OS) and disease-free survival
(DFS) rates in our patient group were 18.7 months (95%
CI: 12.4-25.6 months) and 10.0 months (95% CI: 7.4-12.4
months), respectively. Uni- and multivariable Cox regres-
sion analyses were performed to identify predictors of
DFS and OS rates after pancretic resection with curative
intent. The common closing date was the 1st of July 2011.
Variables considered were dichotomized expression values
of the genes of interest and clinico-pathological variables:tumour localisation in the pancreas (head/corpus/tail),
tumour size (< 20mm, 20-40mm, > 40mm), tumour differ-
entiation grade (pG), pT, pN, pM, extracapsular lymph
node involvement (ECLNI), perineural invasion (PNI),
lymphovascular invasion (LVI), vascular invasion (VI), re-
section margin status (R), minimal resection margin >
1mm, adjuvant chemotherapy within the first 3 months
after surgery. The cut-off for dichotomisation of gene ex-
pression values was the median fold change calculated for
every gene. All variables with p-values ≤ 0.10 in univa-
riable analysis were considered for the final multivariable




Cytospins after FACsorting of the high Panc-1 concen-
tration whole-blood samples showed marked cytoplas-
matic prekeratin staining of >90% cells, indicating that
this fraction was composed almost exclusively of epithe-
lial cells. Omnipresent large nuclei with prominent nu-
cleoli demonstrated the malignant nature of these cells,
indicating that these were the spiked Panc-1 cells
(Figure 3A). In contrast to the CTC-fraction, the G-
fraction in both sortings was composed mainly of
PMBCs (>75%), very few larger cells with prominent
cytoplasmatic prekeratin staining (Panc-1 cells) and cel-
lular debris (Figure 3B).
Similarly, 5.0 × 104 Panc-1 cells (low concentration)
were spiked in 20ml of EDTA-treated whole blood. The
cytospins’ cell density was greatly reduced owing to the
lower concentration of spiked Panc-1 cells and lower re-
covery of spiked cells. Despite varying cell size, marked
cytoplasmatic prekeratin staining in the CTC-fraction
could be demonstrated (Figure 3C). On the other hand,
the G-fraction was composed almost exclusively of
PBMCs similar to the G-fraction after sorting of the high
Panc-1 concentration. Estimation of the recovery after
spiking, density centrifugation, FACsorting and cytospins
was not attempted.
RNA purity and integrity
Similar to enrichment procedures used in our spiking
experiments, blood of ten patients (Table 1) was sorted
into two fractions (CTC and G). A median number of
1,828 (range: 761 – 33,337) presumed CTC was obtained
for RNA extraction. A260/A280 ratios were > 1.80 for
all samples. Tissue samples (T and P) were obtained with
good RNA integrity numbers (RIN) ≥ 7.5, except for
samples T123 and P138, which had a RIN of 7.1 and 6.9,
respectively. The RNA quality standards set for micro-
array analysis were reached in 6 out of 10 patients for all
4 subgroup samples, i.e. for the CTC, G, T and P sam-
ples the median starting amount of RNA converted and
Figure 3 A. Prekeratin staining of cytospins of sorted CTC fraction after spiking 5.0 × 106 Panc-1 cells in 20ml EDTA-treated whole
blood. Note the marked cytoplasmatic prekeratin staining of almost all sorted cells indicating very high purity of the sorted fraction. The stained
cells have large blue nuclei with prominent nucleoli (arrow) indicating the malignant nature of the enriched PANC-1 cells. PBMCs are marked
with an arrowhead. Magnification: 30x, Bars: 25μm. B - Prekeratin staining of cytospins of sorted ‘gated’ fraction (G) after spiking 5.0 × 106 Panc-1
cells in 20ml EDTA-treated whole blood. The sample is mainly composed of two cell types: most are PBMCs with a little amount of non-staining
cytoplasma (arrowheads) and a few larger cells with prominent cytoplasmatic prekeratin staining (Panc-1 cells) (arrows). Magnification: 10x, Bars:
25μm. 3C - Prekeratin staining of the sorted CTC fraction after spiking 5.0 × 104 Panc-1 cells in 20ml EDTA-treated whole blood. Cell density is
greatly reduced owing to the lower concentration of spiked Panc-1 cells. Despite varying cell size, marked cytoplasmatic prekeratin staining was
seen in most cells, indicating high purity of the sorted cells. Magnification: 10x, Bars: 25μm.
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0.49), 8.00ng (range: 0.528 – 10), 10ng (range: 5–10) and
10ng (range: 5 – 10), respectively.Gene expression analysis
For 46,467 probes, fewer than 4 out of 6 CTC samples
gave present detection calls and therefore these probes
were omitted from further analysis (Additional file 1).
We retained a final set of 8,152 probes for statistical
analysis. Differential gene expression was observed be-
tween CTC and T samples for 3,570 genes, of which
1,645 genes were significantly upregulated and 1,925
genes downregulated (Table 2). Between CTC and P
samples a total of 3,669 genes were differentially
expressed. Only 6 genes were found to be significantly
upregulated in T vs. P samples, i.e. S100 calcium binding
protein (S100P), tubulin α-4a (TUBA4A), interleukin 1
receptor antagonist (IL1RN), epithelial cell transforming
sequence 2 oncogene (ECT2), stratifin (SFN), and
chromosome 19 open reading frame 33 (C19orf33). NoTable 2 Counts of down- and upregulated genes
Corrected p-value < 0.05
Log-ratio < −1 Log-ratio > +1
CTC vs T 1,925 1,645
CTC vs P 1,951 1,718
CTC vs G 825 905
T vs P 0 6
T vs G 1,139 1,089
P vs G 1,253 1,128
Log-ratio < −1 indicates significant 2-fold downregulation; Log-ratio > +1
indicates significant 2-fold upregulation.genes were found to be significantly downregulated in T
vs. P samples.
Molecular network and pathway analysis
To avoid probes referring to the same molecule in the
IPA application, a maximum of fold-change values was
taken. In order to compare CTC vs. T, AND CTC vs. P,
AND CTC vs. G fractions, only genes with a significant
2-fold up– or downregulation were selected (corrected
p-values < 0.05). This selection resulted in a total of
1,059 probe sets. Among these 1,059 differentially
expressed genes, 738 molecules were eligible to generate
gene networks with the Ingenuity Pathway Analysis soft-
ware, and a total of 572 molecules were eligible for the
generation of cellular functions and pathways. Primary
functions involved in the top gene network were cancer,
cell death, and neurological disease, with transforming
growth factor β1 (TGF-β1) as the core molecule
(Additional file 2) TGF-β1 was found to be highly upre-
gulated in the CTC fraction compared to the T, P, and G
fractions, with a fold change (FC) of 3.18, 3.33, and 2.16,
respectively. The three most important biofunctions for
the category ‘Diseases and Disorders’ were inflammatory
response (6.6E-04 < p-value < 4.81E-02), cancer (1.69E-
03 < p-value < 3.92E-02), and genetic disorders (1.69E-
03 < p-value < 3.92E-02). The three most important
‘Molecular and Cellular functions’ were cell-to-cell sig-
naling and interaction (7.84E-04 < p-value < 4.98E-02),
cellular development (2.47E-03 < p-value < 4.81E-02), and
cellular movement (5.22E-03 < p-value < 4.74E-02).
P-values were calculated with the Ingenuity Pathway Ana-
lysis program using the right-tailed Fisher's Exact Test
and represent a measure of its statistical significance with
respect to the functions for the dataset and the references
Table 3 Median (range) fold change PDAC/control tissue
(nCounter) for the validation set
Gene Fold change
Median Range
TLN1 12.10 10.62 – 15.29
STAT3 12.10 10.90 – 13.07
VCL 11.59 9.99 – 12.56
CCL5 9.82 7.67 – 11.79
AMFR 10.73 9.73 – 11.54
TPM4 14.26 12.67 – 15.64
ALOX12 0 (0.44) * 0 – 6.45
ARHGEF2 10.21 8.44 – 10.97
ELMO1 7.66 5.53 – 9.00
TGF-β1 10.74 8.76 – 11.64
MAX 10.83 9.56 – 11.38
PLA2G4C 6.73 4.89 – 8.49
* between parenthesis is mean.
Table 4 Univariable and multivariable Cox regression
analysis for disease-free survival
Univariable Multivariable
p-value HR (95% CI) p-value HR (95% CI)
Tumor
location
0.105 1.628 (0.898 – 2.822) 0.065 0.557 (0.310 – 1.038)
pG 0.046 0.031
1 0.597 (0.229 – 1.848) 0.431 (0.158 – 1.372)
2 1.207 (0.522 – 3.504) 0.899 (0.377 – 2.658)
3 2.023 (1.155 – 3.724) 2.089 (1.184 – 3.872)
TNM
stage





0.033 1.903 (1.053 – 3.530) 0.041 1.885 (1.025 – 3.559)
HR (95% CI) hazard ration with 95% confidence interval, pG tumor
differentiation.
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been functions eligible).
The pathway with the highest expression ratio (10.5%)
was p38 mitogen-activated protein kinase (MAPK) signal-
ing. This ratio was calculated as the number of molecules
in a given pathway that met cut-off criteria (n=10) divided
by the total number of molecules making up that pathway
(n=95). In the p38 MAPK pathway TGF-β1, cytosolic
phospholipase A2 (cPLA2), and MYC associated factor X
(MAX) were significantly upregulated in the CTC fraction
as compared to the T, P, and G fractions (p < 0.05). In
addition, using the gene ontology application software
AmiGO, the list of upregulated genes associated with both
p38 MAPK signaling and cell motility was mapped. This
resulted in a set of 9 genes, i.e. arachidonate 12-
lipoxygenase (ALOX12), autocrine motility factor receptor
(AMFR), Rho-guanine nucleotide exchange factor 2
(ARHGEF2), CCL5, engulfment and cell motility protein
(ELMO1), signal transducer and activator of transcription
3 (STAT3), Talin-1 (TLN1), Tropomyosin alpha-4 chain
(TPM4) and Vinculin (VCL).
Clinically prognostic value of cell motility gene signature
Using the nCounter system, expression values of 12
genes (Table 3) obtained from the microarray data were
studied in 78 PDAC samples, and represented as the
median (range) fold change expression of tumour vs.
controls. Univariable Cox regression analysis did not
show any significant correlation between the continuous
fold change values and survival. After dichotomization a
significant correlation was found on univariable analysis
for TGF-β1 and DFS (p=0.05, HR (95% CI) = 1.903
(1.053 – 3.530)). For OS, a correlation was found but it
did not reach statistical significance (p=0.08, HR (95%
CI) = 1.56 (0.94 – 2.62)). Next, a combined variable was
created containing information on TGF-β1 and the
number of motility genes expressed above the median in
the validation set. When the fold change of ≥ 4 of the 9
motility genes and/or TGF-β1 was high, DFS was signifi-
cantly worse on univariable analysis (p=0.033, HR (95%
CI) = 1.84 (1.04 – 3.46)) (Table 4 and Figure 4). When
the fold change of ≥ 6 of the 9 motility genes and/or
TGF-β1 was high, worse OS was found (p=0.067, HR
(95% CI) = 1.734 (0.962 – 3.132)) (Table 5 and Figure 5).
On multivariable analysis, high co-expression of TGF-
β1 and the cell motility panel (≥ 4 out of 9 genes for
DFS and ≥ 6 out of 9 genes for OS) were identified as an
independent predictor of both DFS (p=0.041, HR (95%
CI) = 1.885 (1.025 – 3.559)) and OS (p=0.047, HR (95%
CI) = 1.366 (1.004 – 1.861)) respectively (Table 4 and 5).
Discussion
Identification of specific genetic and phenotypic changes
occurring in CTC could result in a better understandingof the metastatic process and lead to effective thera-
peutic strategies [12]. To our knowledge, for the first
time global gene expression profiles were generated from
blood enriched for CTC by a negative depletion tech-
nique. Depletion of dead (7AAD staining) and non-
epithelial cell types (such as leukocytes (CD45+) and
other endothelial/leukocyte progenitor cells (CD34+)
results in a more unbiased enrichment of CTC both in
spiking experiments and in vivo compared to a priori
positive selection using epithelium-specific antibodies.
An important issue in small-sample gene expression
microarray analyses is the quality of the final RNA sam-
ple. Indeed, all methods requiring additional steps (e.g.
tissue biopsies from resection specimens, density centri-
fugation, FACS) to acquire very small amounts of cells
bear the risk of RNA degradation. Moreover, the pan-
creas is known for its high concentration in RNases,
Figure 5 Kaplan-Meier estimated overall survival for the
validation set. p-values for tests between groups were p=0.155
(Log-Rank) and p=0.018 (Wilcoxon). Grouping was done according
to overexpression of ≥ 6 motility genes or/and TGF-β1. No
overexpression of ≥ 6 motility genes or TGF-β1 = group 0 (red).
Overexpression of ≥ 6 motility genes or TGF-β1 = group 1 (green).
Overexpression of ≥ 6 motility genes and TGF-β1 = group 2 (blue).
Figure 4 Kaplan-Meier estimated disease-free survival for the
validation set. p-values for tests between groups were p=0.099
(Log-Rank) and p=0.028 (Wilcoxon). Grouping was done according
to overexpression of ≥ 4 motility genes or/and TGF-β1. No
overexpression of ≥ 4 motility genes or TGF-β1 = group 0 (red).
Overexpression of ≥ 4 motility genes or TGF-β1 = group 1 (green).
Overexpression of ≥ 4 motility genes and TGF-β1 = group 2 (blue).
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minimize this effect, periods of warm ischemia between
removal of the surgical specimen and sample processing
were kept to a strict minimum. Also, tissue samples
were immediately submerged into a RNA stabilizing
agent (RNAlaterW) and care was taken to store these
samples under optimal conditions. Despite these strin-
gent precautions moderate degradation was observed in
a substantial number of samples. Nevertheless, moderate
RNA degradation probably disturb microarray results
only modestly [13], and the final number of samples
with high-quality RNA was sufficient to draw sound
conclusions from the present study. Microarray analysesTable 5 Univariable and multivariable Cox regression
analysis for overall survival
Univariable Multivariable
p-value HR (95% CI) p-value HR (95% CI)
pG 0.053 0.293
1 0.738 (0.232 - 3.267) .718 (0.220 – 3.220)
2 1.508 (0.545 – 6.251) 1.191 (0.418 – 5.004)
3 2.042 (1.132 – 3.922) 1.658 (0.885 – 3.312)
TNM
stage
0.007 2.986 (1.394 – 5.828) 0.015 2.715 (1.234 – 5.499)
ECLNI 0.016 1.974 (1.141 – 3.361) 0.032 1.870 (1.057 – 3.268)





0.067 1.734 (0.962 – 3.132) 0.047 1.366 (1.004 – 1.861)
HR (95% CI) hazard ration with 95% confidence interval, pG tumor
differentiation, pT tumor stage, ECLNI extracapsular lymph node involvement,
PNI perineural invasion.showed differential gene expression profiles between the
CTC, T, P and G fractions. In contrast to other reports,
we found only 6 genes (C19orf33, ECT2, IL1RN, S100P,
SFN, TUBA4A) to be significantly upregulated in the
primary PDAC (T) as compared to the non-tumoural
pancreatic tissue (P) samples, whilst no genes were
found to be downregulated. This finding can be
explained by the fact that the ductal epithelial cells, of
which PDAC originates, make up only a small propor-
tion of the bulk surrounding pancreas or tumour. In-
deed, expression profiles often predominantly reflect the
proportion of cell types and obscure more meaningful
data. Another explanation may be that we finally
retained only 8,152 probe sets out of 46,467 probes ini-
tially tested, because Robust Multichip Average (RMA)
was applied only to probe sets with a present detection
call in at least 4 out of 6 CCD samples.
In our stringent comparison of the various cell frac-
tions (CTC vs. T, AND CTC vs. P, AND CTC vs. G), the
top molecular and cellular functions expressed in CTC
were cell-to-cell signalling and interaction, cellular de-
velopment, and cellular movement. The pathway with
the highest expression ratio in CTC was p38 MAPK sig-
nalling, which is known to be involved in biological pro-
cesses such as inflammation, apoptosis, and cell
differentiation [14]. More recently, the p38 MAPK sig-
nalling cascade was also shown to play a pivotal role in
cancer cell migration, and could be stimulated by
S100A8 [14]. Moreover, potential secretion of TNFα,
VEGF-A and TGF-β1 from primary tumours induced
S100A8 and S100A9, which in turn stimulated the en-
richment of other inflammatory chemo-attractants.
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tivity in CTC could occur in response to S100A8 pro-
duced not only in homing organs (such as lungs, liver)
but also in CTC. Stimulation of p38 MAPK by S100A8
has been shown to induce formation of pseudopodia im-
portant to dynamic cell movement in the process of in-
vasion and extravasation [15]. Therefore, we used the
gene ontology application software AmiGO at other
genes that were overexpressed in CTC involved in the
same process and in p38 MAPK signalling. Other genes
mediating many of the component processes of invasion
include Talin-1 and ELMO1. Both these genes were
found to be upregulated in our CTC. Besides these
genes, we found another 7 genes, i.e. ALOX12, AMFR,
ARHGEF2, CCL5, STAT3, TPM4, and VCL. These 9
genes were termed CTC motility panel for ease of
formulation.
In the p38 MAPK pathway TGF-β1, cPLA2, and MAX
were significantly upregulated in CTC. TGF-β1 regulates
a spectrum of cellular events, including cell proliferation,
differentiation, and migration. In addition to the canon-
ical Smad pathway, TGF-β1 can also activate MAPK,
phosphatidylinositol 3-kinase (PI3K)/Akt and small
GTPases in a cell-specific manner. Activation of ERK or
p38 MAPK is required for both TGF-beta-induced
epithelial-mesenchymal transition (EMT) and cell mi-
gration [16]. Reversible and local activation of TGFβ/
Smad-signalling in breast cancer cells has recently been
shown to cause a switch from cohesive movement to
single cells motility and to promote haematogenous me-
tastasis [17].
A clear association has been described between the
CCL5/CCR5 axis and the directional migration and
invasion of human cancer cells. In vitro, this has
been shown to involve specific upregulation of matrix-
metalloproteinase-9 (MMP-9) [18]. STAT3 is a tran-
scription factor that has been linked with metastasis in
different tumourtypes e.g. lung, colon adenocarcinoma,
and PDAC [19]. Besides increasing cell motility and in-
vasion, STAT3 is also thought to upregulate the expres-
sion of anti-apoptotic and growth-promoting genes and
to facilitate the colonisation of the liver by tumour cells
[20,21]. Therefore, STAT3 could be another new target
for prevention of metastasis formation by CTC and for
the treatment of established metastasis. STAT3 inhibi-
tors are already available and currently undergo testing
in various animal cancer models [20].
Our study provides a valuable source for researchers
to explore. Using a negative depletion technique we were
capable of isolating CTC, without using a priori selec-
tion markers. We have identified several candidate genes
in CTC from PDAC, which can be used for various pur-
poses. First, a combination of these genes may distin-
guish between benign and malignant disease of thepancreas. This was beyond the scope of this study. Also,
as these genes represent the molecular signature of CTC
in peripheral blood they may be useful for disease moni-
toring, prediction of survival, and response to therapy.
Therefore we determined the expression level of our cell
motility gene signature in 78 independent PDAC sam-
ples using the nCounter system. This system uses digital
technology based on direct multiplexed measurement of
gene expression, and offers high levels of sensitivity and
precision [22]. We found that the combination of ex-
pression of our CTC motility panel and TGF-β1 identi-
fied a subgroup of primary PDAC at high risk of early
recurrence and worse overall survival. Some of these
genes may also be interesting therapeutic targets and
need further exploration.However, we should remain
cautious as measurement of mRNA levels to infer
events at the protein level can be misleading, as discor-
dances may exist between mRNA levels and encoded
protein levels.
Conclusion
Pancreatic CTC isolated from blood samples using a
FACS-based negative depletion method, express a cell
motility gene signature. The expression of this newly
defined cell motility gene signature in the primary
tumour enables us to predict survival of patients who
undergo surgical resection for pancreatic cancer. The ex-
pression of this gene signature may be used as a selection
tool in patients who are candidates for surgery, not only
in pancreatic but also in other solid organ malignancies.
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